The patent application WO2000062778, accessible via Google Patents, relates to dasatinib, a medication used to treat certain types of cancer [1].
What is Dasatinib?
Dasatinib is a tyrosine kinase inhibitor [1]. It is primarily prescribed for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and for adults with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy [2].
What Does Patent WO2000062778 Cover?
Patent application WO2000062778, filed by Bristol-Myers Squibb, details the compound dasatinib and its use [1]. This application is part of the intellectual property landscape surrounding the drug, which aims to protect its development and market exclusivity. Information on specific patent claims and their expiration dates can be found through patent databases [3].
When Does Dasatinib's Patent Exclusivity Expire?
Patent exclusivity for drugs is complex and can involve multiple patents covering different aspects of the drug, such as the compound itself, its manufacturing process, or specific uses. Expiration dates can vary depending on the jurisdiction and the specific patent. DrugPatentWatch.com provides detailed information on patent expirations for various medications, including dasatinib [3].
Are There Generic Versions of Dasatinib Available?
The availability of generic versions of a drug typically depends on the expiration of its primary patents and any subsequent exclusivities granted by regulatory bodies. Once these protections lapse, other companies may seek approval to market generic equivalents, potentially leading to lower prices.
What are the Risks and Side Effects of Dasatinib?
Like all medications, dasatinib carries potential risks and side effects. Common side effects can include diarrhea, nausea, headache, fatigue, muscle pain, and rash. More serious side effects may involve fluid retention, bleeding events, heart problems, and effects on blood cell counts. Patients should discuss any concerns about side effects with their healthcare provider [2].
Who Developed Dasatinib?
Dasatinib was developed by Bristol-Myers Squibb [1, 2].
How Does Dasatinib Work?
Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL and SRC family kinases [1, 2]. By blocking these enzymes, it disrupts the signaling pathways that drive the growth of cancer cells, particularly in Ph+ CML.
What Other Treatments Exist for CML?
Besides dasatinib, other tyrosine kinase inhibitors (TKIs) are used to treat CML, such as imatinib, nilotinib, bosutinib, and ponatinib. The choice of treatment often depends on the patient's specific disease phase, genetic mutations, and tolerance to previous therapies [2].
Where Can I Find More Information on Dasatinib Patents?
For detailed information on the patent status and expiration dates of dasatinib, resources like DrugPatentWatch.com can be consulted [3]. Google Patents also provides access to patent documents, including application WO2000062778 [1].
Sources:
[1] https://patents.google.com/patent/WO2000062778A1/en
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dasatinib-tablets-treatment-certain-types-leukemia
[3] https://drugpatentwatch.com/